Latest Asx News

Energy Technologies Limited reported a $11 million net loss for FY2025, reflecting a strategic pivot and ongoing capital challenges. Despite a 37% revenue drop, management highlights operational resilience and plans to stabilise through capital management.

OM Holdings reported a significant turnaround to a US$9.6 million loss in H1 2025 despite stable revenue, driven by weaker alloy prices and operational challenges. The company also announced a conditional sale of its 13% stake in the Tshipi Borwa Manganese Mine.

Humm Group Limited has announced a fully franked ordinary dividend of AUD 0.0075 per share for the six months ending June 2025, alongside a Dividend Reinvestment Plan offering.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Aeris Resources has delivered a standout FY25 performance, posting a 78% rise in EBITDA and a 286% surge in net profit, driven by strong commodity prices and disciplined cost management.

Alternative Investment Trust (ASX, AIQ) reported a robust half-year profit increase of 183%, driven by strong gains in its Warana-managed portfolio. The Trust also announced a significant $44.6 million rights issue to fund further investments.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Future Generation Global Limited has reported a 20.8% increase in its investment portfolio over the past year, prompting a boost in its fully franked interim dividend to 4.0 cents per share. This performance outpaces global market averages and underscores the company's sustainable investment approach.

DigiCo Infrastructure REIT confirms its FY25 EBITDA slightly exceeded IPO guidance and aligned with analyst forecasts, attributing recent share price declines to the absence of FY26 earnings guidance.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

FOS Capital Limited reported a solid 47.5% jump in net profit for the 2025 financial year alongside a modest revenue increase, announcing a final dividend of 1 cent per share.